Evaluation of gemfibrozil therapy: predictive response from lipoprotein subfraction analysis

Area of Science:

• Cardiology
• Clinical Lipidology
• Pharmacogenomics

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is a significant cardiovascular risk factor.
• Gemfibrozil is a lipid-regulating drug with variable efficacy.
• Understanding predictors of gemfibrozil response is crucial for personalized therapy.

Purpose of the Study:

• To identify pretreatment lipid parameters that predict gemfibrozil therapy efficacy.
• To analyze changes in plasma lipoprotein subfractions in response to gemfibrozil.
• To understand the variability in HDL-C and triglyceride response to gemfibrozil.

Main Methods:

• Selected subjects with baseline HDL-C < 47 mg/dL.
• Analyzed serum samples before and after 12 weeks of gemfibrozil therapy.
• Used multiple regression analysis to develop predictive models based on lipoprotein subfractions.

Main Results:

• Developed a predictive model using specific lipoprotein subfractions with 78% accuracy for classifying responders vs. nonresponders.
• Identified a significant correlation between HDL-C increase and triglyceride lowering in responders (r = 0.61, p = 0.03).
• Nonresponders showed no significant correlation between HDL-C changes and triglyceride lowering (r = 0.17, p = 0.52).

Conclusions:

• Specific pretreatment lipoprotein subfractions can predict individual response to gemfibrozil therapy.
• The correlation between HDL-C changes and triglyceride reduction differs significantly between responders and nonresponders.
• The predictive model accurately forecasts gemfibrozil's triglyceride-lowering effectiveness.